吉西他宾联合奥沙利铂方案介入化学治疗局部复发鼻咽癌的临床观察

发布时间：2019-03-27 15:31

【摘要】：目的探讨吉西他滨联合奥沙利铂(GEMOX)方案介入化学治疗局部复发鼻咽癌的疗效和安全性。方法收集2007年11月-2013年3月共41例接受GEMOX方案介入化学治疗的局部复发鼻咽癌患者,具体用药为:吉西他滨1 000 mg/m2动脉灌注,第1天,吉西他滨1 000 mg/m2静脉滴注,第8天;奥沙利铂100mg/m2动脉灌注,第1天,21天为1周期,2个周期后评价疗效。结果 41例患者共完成82个周期化疗,每例均接受2个周期。41例患者均可评价疗效和毒副反应,获CR10例(24.4%),PR26例(63.4%),SD4例(9.8%),PD1例(2.4%),总有效率(RR)为87.8%,疾病控制率(DCR)为97.6%。主要毒副反应为局部疼痛、白细胞减少、血小板减少、恶心呕吐和肝功能损害,均以1、2级为主。结论 GEMOX方案介入化学治疗局部复发鼻咽癌疗效好,毒副反应可耐受,值得临床进一步应用。
[Abstract]:Objective to evaluate the efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX) regimen in the treatment of locally recurrent nasopharyngeal carcinoma (NPC). Methods from November 2007 to March 2013, 41 patients with locally recurrent nasopharyngeal carcinoma underwent interventional chemotherapy with GEMOX regimen. The specific drugs were gemcitabine 1 000 mg/m2 arterial infusion, day 1, gemcitabine 1 000 mg/m2 intravenous drip, Day 8; Oxaliplatin 100mg/m2 was perfused into artery on day 1 and day 21, and the efficacy was evaluated after 2 cycles. Results A total of 82 cycles of chemotherapy were completed in 41 patients, and each patient received 2 cycles. All 41 patients were able to evaluate the efficacy and side effects. CR10 (24.4%), PR (63.4%), SD (4 cases) (9.8%) were obtained. The total effective rate (RR) and disease control rate (DCR) of PD1 (2.4%) were 87.8% and 97.6% respectively. The main side effects were local pain, leukopenia, thrombocytopenia, nausea, vomiting and liver function damage. Conclusion Interventional chemotherapy with GEMOX regimen is effective and tolerable in the treatment of locally recurrent nasopharyngeal carcinoma, which is worthy of further clinical application.
【作者单位】：南华大学附属南华医院肿瘤科;
【基金】：国家自然科学基金(No:81272960) 湖南省科技厅项目(No:2013WK2010) 湖南省卫生厅项目(No:B2012-047) 湖南省教育厅项目(No:12C0343)
【分类号】：R739.63

【参考文献】